View Past PerformanceThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOncopeptides 대차대조표 건전성재무 건전성 기준 점검 2/6Oncopeptides 의 총 주주 지분은 SEK-8.4M 이고 총 부채는 SEK113.6M, 이는 부채 대 자기자본 비율을 -1348.4% 로 가져옵니다. 총자산과 총부채는 각각 SEK199.7M 및 SEK208.1M 입니다.핵심 정보-1,348.42%부채/자본 비율SEK 113.65m부채이자보상배율n/a현금SEK 104.83m자본-SEK 8.43m총부채SEK 208.12m총자산SEK 199.69m최근 재무 건전성 업데이트공시 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.모든 업데이트 보기Recent updates공시 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.공시 • Apr 17Oncopeptides AB (publ), Annual General Meeting, May 22, 2025Oncopeptides AB (publ), Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Location: at tandstickspalatset, vastra tradgardsgatan 15, stockholm Sweden공시 • Apr 16Oncopeptides AB (publ) Announces the Publication of New Real-World Data That Further Support the Effectiveness and Tolerability of Melflufen, Refractory Multiple MyelomaOncopeptides AB (publ) announced the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations. The data underline Pepaxti's role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy.공시 • Mar 03Oncopeptides AB (publ) to Report Q1, 2025 Results on May 15, 2025Oncopeptides AB (publ) announced that they will report Q1, 2025 results on May 15, 2025공시 • Feb 20Oncopeptides AB (publ) to Report Q4, 2024 Results on Feb 27, 2025Oncopeptides AB (publ) announced that they will report Q4, 2024 results at 8:00 AM, Central European Standard Time on Feb 27, 2025공시 • Feb 06Jarl Ulf Jungnelius Resigns from Oncopeptides AB (publ) Board of DirectorsOncopeptides AB (publ) announced that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.공시 • Jan 27Oncopeptides' Pepaxti Formally Approves for Full Reimbursement in ItalyOncopeptides AB (publ) announced that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal ("IOJ", It.: Gazetta Ufficiale). This marks the final regulatory step for the drug's upcoming commercialization in Italy, confirming Oncopeptides' expectation of first sales during first half, 2025. With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company's goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months. Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti's target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement. As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.공시 • Jul 04An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million on July 2, 2024. Industrifonden Foundation has divested its entire stake in Oncopeptides. An undisclosed buyer completed the acquisition of 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden on July 2, 2024.공시 • May 17Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy CongressOncopeptides AB (publ) announced that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Cont Cont Cont Controversies in Multiple Myeloma (COMy), to be held on May 23-26. The study, published by a team from institutions across Europe, including the University of Wurzburg and the Institute for Molecular Medicine Finland, focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma. The study will be presented to congress attendees through an online oral presentation on May 26. The presentation will be given by Caroline Heckman, from the Institute for Molecular Medicine Finland. Multiple myeloma can be especially difficult to treat in patients who have specific genetic mutations or deletions, such as del(17p) and/or mutations in the TP53 gene. These genetic characteristics are associated with a poorer prognosis and shorter survival rates. The research findings indicate that melflufen is more effective than traditional alkylating agents causing DNA damage and promoting the death of cancer cells lacking a functional so-called p53 protein, which is a common issue in high-risk multiple myeloma cases. The study also highlighted significant changes in gene expression that enhance the drug's impact on cancer cells. Furthermore, patients with the del(17p) genetic abnormality treated with melflufen and dexamethasone showed a longer progression-free survival and higher overall response rate compared to those treated with pomalidomide and dexamethasone in the OP-103 OCEAN trial.공시 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).공시 • Mar 13Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering공시 • Feb 24Oncopeptides AB (publ), Annual General Meeting, May 22, 2024Oncopeptides AB (publ), Annual General Meeting, May 22, 2024.공시 • Dec 16Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier LinesOncopeptides announced that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains. Oncopeptides has submitted an application to adjust the indication of Pepaxti to the originally approved indication, a process that is expected to be finalized in early 2024. During this time, Oncopeptides will work together with the European Commission, EMA as well as local stakeholders to ensure an efficient removal process for the extended indication.공시 • Nov 18Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Oncopeptides AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024공시 • Nov 15Oncopeptides Selects to Present Additional Data from Ocean StudyOncopeptides AB (publ) announced that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. ASH is the world's professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.공시 • Oct 27Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024Oncopeptides AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Aug 14, 2024공시 • Oct 21Oncopeptides AB (publ) Announces the Nomination CommitteeOncopeptides AB (publ) announces that the composition of the Nomination Committee has been established. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors. The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023. Staffan Lindstrand, appointed by HealthCap VI L.P., Patrik Sobocki, appointed by Stiftelsen Industrifonden, Caroline Mebius, appointed by Handelsbanken funds, and Per Wold-Olsen, the Chairman of the Board.공시 • Oct 12Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024Oncopeptides AB (publ) announced that they will report Q1, 2024 results on May 03, 2024공시 • Oct 02Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 final results on Apr 22, 2024공시 • Sep 21Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024공시 • Sep 15Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial ResultsOncopeptides AB (publ) announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides' application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision. Based on findings from its OCEAN trial, Oncopeptides submitted, on 28 Nov. 2022, an application to extend the therapeutic indication of Pepaxti to the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy. With their opinion, CHMP recommends that the use of Pepaxti could be expanded to earlier lines of treatment and also peripheral administration, meaning delivery of treatment through peripheral rather than central veins, a less invasive way of administration. Oncopeptides will as a next step assess the current market dynamics of the rapidly evolving multiple myeloma landscape, including the competition in different lines of treatment and the effect that extending Pepaxti into earlier lines of treatment would have on Oncopeptides's ability to receive a reimbursed price that reflects its innovation.공시 • Aug 10Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial OfficerOncopeptides AB (publ) announced that the company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.공시 • Aug 08+ 1 more updateOncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO RoleOncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.공시 • Jun 14Holger Lembrér Will Leave Oncopeptides as Chief Financial OfficerOncopeptides AB (publ) announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately.공시 • Feb 18+ 2 more updatesOncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023Oncopeptides AB (publ) announced that they will report Q2, 2023 results on Aug 10, 2023공시 • Jan 12Oncopeptides AB (Publ) Announces Chief Financial Officer ChangesOncopeptides AB (publ.) announced that the company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining the company, Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.공시 • Jan 05Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific OfficerOncopeptides AB (publ) announced that the Board of Directors has appointed Dr. Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.공시 • Jan 04Oncopeptides AB (Publ) Announces Executive ChangesOncopeptides AB (publ.) announced that the board of directors has appointed Dr. Monica Shaw as chief executive officer of the company. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately. Dr. Monica Shaw brings a wealth of executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to successful commercialization, globally and across many geographies. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, including Immunology, Oncology, Virology, Neurology and Rare Diseases.공시 • Dec 15Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 25, 2023공시 • Feb 18Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023재무 상태 분석단기부채: ONPP.F 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.장기 부채: ONPP.F는 마이너스 주주 지분을 갖고 있어 장기 부채를 충당하지 못하는 단기 자산보다 더 심각한 상황입니다.부채/자본 비율 추이 및 분석부채 수준: ONPP.F 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.부채 감소: ONPP.F는 주주 지분이 음수이므로 부채가 시간이 지남에 따라 감소했는지 확인할 필요가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: ONPP.F 은 마지막 보고 무료 현금 흐름을 기준으로 5 개월 동안 충분한 현금 활주로를 보유하고 있지만 이후 추가 자본을 조달했다.예측 현금 활주로: ONPP.F 은 잉여현금흐름추정을 기준으로 10 개월 동안 충분한 현금 활주로를 확보할 것으로 예상되지만 이후 추가 자본을 조달했습니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/07/31 07:15종가2024/05/03 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oncopeptides AB (publ)는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Erik HultgårdCarnegie Investment Bank ABPatrik LingDNB CarnegieErik HultgårdDNB Carnegie4명의 분석가 더 보기
공시 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.
공시 • May 06Oncopeptides AB's Ordinary Shares to be Deleted from OTC EquityOncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security.
공시 • Apr 17Oncopeptides AB (publ), Annual General Meeting, May 22, 2025Oncopeptides AB (publ), Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Location: at tandstickspalatset, vastra tradgardsgatan 15, stockholm Sweden
공시 • Apr 16Oncopeptides AB (publ) Announces the Publication of New Real-World Data That Further Support the Effectiveness and Tolerability of Melflufen, Refractory Multiple MyelomaOncopeptides AB (publ) announced the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations. The data underline Pepaxti's role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy.
공시 • Mar 03Oncopeptides AB (publ) to Report Q1, 2025 Results on May 15, 2025Oncopeptides AB (publ) announced that they will report Q1, 2025 results on May 15, 2025
공시 • Feb 20Oncopeptides AB (publ) to Report Q4, 2024 Results on Feb 27, 2025Oncopeptides AB (publ) announced that they will report Q4, 2024 results at 8:00 AM, Central European Standard Time on Feb 27, 2025
공시 • Feb 06Jarl Ulf Jungnelius Resigns from Oncopeptides AB (publ) Board of DirectorsOncopeptides AB (publ) announced that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden.
공시 • Jan 27Oncopeptides' Pepaxti Formally Approves for Full Reimbursement in ItalyOncopeptides AB (publ) announced that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal ("IOJ", It.: Gazetta Ufficiale). This marks the final regulatory step for the drug's upcoming commercialization in Italy, confirming Oncopeptides' expectation of first sales during first half, 2025. With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company's goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months. Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti's target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement. As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits.
공시 • Jul 04An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million on July 2, 2024. Industrifonden Foundation has divested its entire stake in Oncopeptides. An undisclosed buyer completed the acquisition of 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden on July 2, 2024.
공시 • May 17Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy CongressOncopeptides AB (publ) announced that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Cont Cont Cont Controversies in Multiple Myeloma (COMy), to be held on May 23-26. The study, published by a team from institutions across Europe, including the University of Wurzburg and the Institute for Molecular Medicine Finland, focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma. The study will be presented to congress attendees through an online oral presentation on May 26. The presentation will be given by Caroline Heckman, from the Institute for Molecular Medicine Finland. Multiple myeloma can be especially difficult to treat in patients who have specific genetic mutations or deletions, such as del(17p) and/or mutations in the TP53 gene. These genetic characteristics are associated with a poorer prognosis and shorter survival rates. The research findings indicate that melflufen is more effective than traditional alkylating agents causing DNA damage and promoting the death of cancer cells lacking a functional so-called p53 protein, which is a common issue in high-risk multiple myeloma cases. The study also highlighted significant changes in gene expression that enhance the drug's impact on cancer cells. Furthermore, patients with the del(17p) genetic abnormality treated with melflufen and dexamethasone showed a longer progression-free survival and higher overall response rate compared to those treated with pomalidomide and dexamethasone in the OP-103 OCEAN trial.
공시 • Apr 05Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).
공시 • Mar 13Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering
공시 • Feb 24Oncopeptides AB (publ), Annual General Meeting, May 22, 2024Oncopeptides AB (publ), Annual General Meeting, May 22, 2024.
공시 • Dec 16Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier LinesOncopeptides announced that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains. Oncopeptides has submitted an application to adjust the indication of Pepaxti to the originally approved indication, a process that is expected to be finalized in early 2024. During this time, Oncopeptides will work together with the European Commission, EMA as well as local stakeholders to ensure an efficient removal process for the extended indication.
공시 • Nov 18Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024Oncopeptides AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024
공시 • Nov 15Oncopeptides Selects to Present Additional Data from Ocean StudyOncopeptides AB (publ) announced that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. ASH is the world's professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
공시 • Oct 27Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024Oncopeptides AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Aug 14, 2024
공시 • Oct 21Oncopeptides AB (publ) Announces the Nomination CommitteeOncopeptides AB (publ) announces that the composition of the Nomination Committee has been established. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors. The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023. Staffan Lindstrand, appointed by HealthCap VI L.P., Patrik Sobocki, appointed by Stiftelsen Industrifonden, Caroline Mebius, appointed by Handelsbanken funds, and Per Wold-Olsen, the Chairman of the Board.
공시 • Oct 12Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024Oncopeptides AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
공시 • Oct 02Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 final results on Apr 22, 2024
공시 • Sep 21Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024Oncopeptides AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024
공시 • Sep 15Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial ResultsOncopeptides AB (publ) announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides' application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision. Based on findings from its OCEAN trial, Oncopeptides submitted, on 28 Nov. 2022, an application to extend the therapeutic indication of Pepaxti to the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy. With their opinion, CHMP recommends that the use of Pepaxti could be expanded to earlier lines of treatment and also peripheral administration, meaning delivery of treatment through peripheral rather than central veins, a less invasive way of administration. Oncopeptides will as a next step assess the current market dynamics of the rapidly evolving multiple myeloma landscape, including the competition in different lines of treatment and the effect that extending Pepaxti into earlier lines of treatment would have on Oncopeptides's ability to receive a reimbursed price that reflects its innovation.
공시 • Aug 10Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial OfficerOncopeptides AB (publ) announced that the company has appointed Henrik Bergentoft as Chief Financial Officer, CFO. Henrik was most recently CFO at RaySearch Laboratories and brings 20+ years of experience from leading finance roles at both medical and non-medical, publicly listed organizations. He will assume his new position during the fourth quarter, replacing Holger Lembrér.
공시 • Aug 08+ 1 more updateOncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO RoleOncopeptides AB (publ) announced that Sofia Heigis who will move from the CCO role to take on the CEO role.
공시 • Jun 14Holger Lembrér Will Leave Oncopeptides as Chief Financial OfficerOncopeptides AB (publ) announced that Holger Lembrér, Chief Financial Officer (CFO) has decided to leave Oncopeptides to pursue a new role in another company. Holger was appointed CFO in January 2023. He will continue in his current role until December or until a new CFO takes office. A recruitment process will be initiated immediately.
공시 • Feb 18+ 2 more updatesOncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023Oncopeptides AB (publ) announced that they will report Q2, 2023 results on Aug 10, 2023
공시 • Jan 12Oncopeptides AB (Publ) Announces Chief Financial Officer ChangesOncopeptides AB (publ.) announced that the company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining the company, Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.
공시 • Jan 05Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific OfficerOncopeptides AB (publ) announced that the Board of Directors has appointed Dr. Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.
공시 • Jan 04Oncopeptides AB (Publ) Announces Executive ChangesOncopeptides AB (publ.) announced that the board of directors has appointed Dr. Monica Shaw as chief executive officer of the company. She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer. These changes are effective immediately. Dr. Monica Shaw brings a wealth of executive leadership skills from the pharmaceutical industry, e.g., GSK and LEO Pharma, and has a strong track record from bringing more than 15 products through phase III to successful commercialization, globally and across many geographies. She has a broad therapeutic area knowledge from previous positions as a physician and within industry, including Immunology, Oncology, Virology, Neurology and Rare Diseases.
공시 • Dec 15Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Apr 25, 2023
공시 • Feb 18Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Oncopeptides AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023